Lung cancer (Figure 5G,H)–Cancers 2021, 13, 5135 Cancers 2021, 13,10 of 18 ten ofGSE30219 (n (n 293 lung tumor samples) [73] and caArray (n = 504 samples) [74], where –GSE30219 = = 293 lung tumor samples) [73] and caArray (n = 504 samples) [74], where high KLF4 levels correlated with worse patient outcomes. high KLF4 levels correlated with worse patient outcomes.Figure KLF4 correlates with patient survival Figure five.five. KLF4 correlateswith patient survival within a cancer-specific manner. (A,B) Relapse-free survival trends inin GSE42568 cancer-specific manner. (A,B) Relapse-free survival trends GSE42568 and GSE3494 (breast cancer),respectively. (C,D) Similar as (A,B) but for the all round survival. (E,F) General survival trends respectively. (C,D) Identical as (A,B) but for the general survival. (E,F) Overall survival trends and GSE3494 (breast cancer), inin GSE26712 and GSE30161(ovarian cancer), respectively. (G,H) General survival trends in GSE30219 and CaArray (lung GSE26712 and GSE30161 (ovarian cancer), respectively. (G,H) General survival trends in GSE30219 and CaArray (lung cancer), respectively. HR denotes the hazard ratio, and logrank P denotes the p-value. The imply worth and 95 self-assurance cancer), respectively. HR denotes the hazard ratio, and logrank P denotes the p-value. The imply value and 95 self-confidence interval are shown. In panel B; 2.2e-05 means two.two 10-5. interval are shown. In panel B; 2.2e-05 signifies two.2 10-5 .Provided that Deguelin supplier higher KLF4 expression associates using a a lot more epithelial phenotype, these Offered that higher KLF4 expression associates with a a lot more epithelial phenotype, these benefits, when extrapolated to indicate the extent of EMT/MET, suggest that EMT associresults, when extrapolated to indicate the extent of EMT/MET, recommend that EMT associates ates with a worse survival in breast cancer but not necessarily in ovarian cancer and lung using a worse survival in breast cancer but not necessarily in ovarian cancer and lung cancer, as far as these limited datasets getting analyzed are concerned. These benefits are cancer, as far as these restricted datasets being analyzed are concerned. These benefits are reminiscent of previous observations that EMT have to have not universally correlate with worse reminiscent of previous observations that EMT require not universally correlate with worse patient survival outcomes and can depend on the cancer variety being investigated [63,75]. patient survival outcomes and can depend on the cancer kind getting investigated [63,75]. Thus, the association of KLF4 with survival seems to be tumor type-specific, and fuTherefore, the association of KLF4 with survival appears to be tumor type-specific, and ture Toceranib phosphate c-Kit studies are required to decipher the interplay in between KLF4 and EMT/MET states as future studies are necessary to decipher the interplay involving KLF4 and EMT/MET states as a prognostic marker of clinical outcomes within a cancer-specific manner. a prognostic marker of clinical outcomes within a cancer-specific manner. three. Discussion three. Discussion We hereby propose KLF4 as prospective MET-inducing transcription aspect (MET-TFs) We hereby propose KLF4 as a a prospective MET-inducing transcription issue (METTFs) based on in silico model predictions and their experimental validation across multibased on in silico model predictions and their experimental validation across various ple in vitro and cancer patient sample datasets. This observation adds for the rising in vitro and cancer patient sample datasets. This observation adds to the incr.
